8-K: NeuroPace Expects Minimal Impact from Tariffs, Reaffirms 2025 Gross Margin Guidance

NeuroPace anticipates minimal impact from international trade tariffs on its operations and financial results and reaffirms its gross margin guidance for fiscal year 2025.

Summary

• NeuroPace, Inc. has released an update on its exposure to international trade tariffs.
• The company anticipates minimal impact on its operations and financial results due to these tariffs.
• NeuroPace manufactures and sells the majority of its devices in the United States and has limited supply chain activities outside the United States for its RNS System.
• The company expects no material impact on gross margin for DIXI Medical SEEG products.
• NeuroPace is reiterating its gross margin guidance for fiscal year 2025.
• NeuroPace previously announced terminating its SEEG distribution agreement with DIXI Medical effective October 1, 2025, followed by a six-month wind down period through the first quarter of 2026.
• The company will report its first quarter 2025 financial results on May 13, 2025, and will host a conference call to discuss the results.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company is managing external factors (tariffs) effectively and reaffirming its financial guidance. There are no significant negative surprises.

Positives

• NeuroPace anticipates minimal impact from international trade tariffs.
• The company is reaffirming its gross margin guidance for fiscal year 2025.
• The company's limited international supply chain mitigates tariff risks.

Risks

• The specific policies and timing of tariff implementation remain fluid, introducing uncertainty.
• Actual operating results may differ significantly from any guidance provided.
• The impact of tariffs could be greater than anticipated, negatively affecting operations and revenue.
• Market acceptance and adoption of the RNS System could impact revenue.
• The company could use its cash resources sooner than expected and may not achieve cash flow breakeven on the anticipated timeline.
• Gross margin for the RNS System may be lower and more negatively impacted by tariffs than forecast.
• Regulatory compliance and expectations for regulatory submissions and approvals could impact market expansion.
• Product development, including AI-powered software, carries inherent risks.
• The company may not be able to meet its long-range plans and revenue projections without DIXI Medical revenue.

Future Outlook

NeuroPace expects minimal impact from tariffs on its operations and financial results and is reiterating its gross margin guidance for 2025. The company is focused on growing its RNS System business and managing the wind-down of the DIXI Medical distribution agreement.

Management Comments

• NeuroPace expects minimal impact to its operations and financial results.
• NeuroPace expects minimal impact to its gross margin for fiscal year 2025 and is reiterating its gross margin guidance for 2025.

Industry Context

In the medical device industry, companies are closely monitoring the impact of international trade tariffs on their supply chains and financial performance. NeuroPace's announcement indicates a relatively insulated position due to its manufacturing and supply chain structure, which is a positive signal for investors compared to companies with more significant international exposure.

Comparison to Industry Standards

• It's difficult to provide a direct comparison to industry standards without specific financial details from NeuroPace and its competitors.
• However, companies like Medtronic, Boston Scientific, and Abbott, which operate globally, have likely been managing tariff impacts through various strategies, such as supply chain diversification and pricing adjustments.
• NeuroPace's focus on US-based manufacturing provides a degree of insulation not shared by all competitors.

Stakeholder Impact

• Shareholders can expect continued focus on managing external economic factors and maintaining financial performance.
• Employees can expect stability in operations due to the company's limited exposure to tariffs.
• Customers (patients with epilepsy) can expect continued access to the RNS System with minimal disruption.

Next Steps

• NeuroPace will report its first quarter 2025 financial results on May 13, 2025.
• The company will host a conference call to discuss the results.

Key Dates

Keywords

NeuroPace, tariffs, gross margin, RNS System, DIXI Medical, financial results, epilepsy, medical device